2026-06-12 · glp-1, microdosing, semaglutide, tirzepatide, compounded glp-1, weight loss medications, off-label · 12 min read

Updated 2026-06-15

What is GLP-1 microdosing?

GLP-1 microdosing means using a sub-therapeutic weekly dose of semaglutide or tirzepatide — typically one-quarter to one-eighth of the labeled chronic-weight-management dose. In practical numbers, that is usually 0.05 to 0.25 mg semaglutide per week, or 0.5 to 2.5 mg tirzepatide per week, compared with labeled maintenance doses of 1.7 to 2.4 mg semaglutide or 10 to 15 mg tirzepatide. It is off-label — no GLP-1 is FDA-approved at microdose levels for weight loss — and is most often supplied through 503A compounding pharmacies operating on a patient-specific prescription basis, or through self-titration from a labeled-dose pen.

Does microdosing work for weight loss?

It produces proportionally less weight loss than the labeled dose. There is no large randomized trial of microdose semaglutide or tirzepatide for chronic weight management. Phase 1 dose-finding data show 0.25 mg semaglutide weekly produces about 1.5 to 3 percent weight loss at 12 weeks, far below the roughly 15 percent at 68 weeks the labeled 2.4 mg dose produced in STEP-1 (Wilding 2021). Anecdotal clinic series suggest 5 to 8 percent loss at 6 months at quarter-doses, but these are unblinded and uncontrolled. If you want STEP-1- or SURMOUNT-1-magnitude loss, you need the labeled dose.

Is GLP-1 microdosing safe?

The class side-effect profile (nausea, constipation, reflux, gallbladder events) appears proportional to dose, so microdosing reports fewer and milder side effects in clinical practice. The honest limit is that long-term safety of indefinite sub-therapeutic dosing has not been studied. The boxed warning for medullary thyroid cancer, the pancreatitis and gallbladder cautions, and the contraindication in pregnancy still apply at any dose. The largest practical risk is product quality: FDA safety communications since 2023 have flagged dosing errors, salt-form confusion, and sterility problems with some compounded GLP-1 supply.

How much does microdosing cost vs a full dose?

Compounded microdose semaglutide commonly runs about $99 to $200 per month in 2026, and compounded microdose tirzepatide about $199 to $350 per month, both cash-pay. Labeled Wegovy 2.4 mg or Zepbound 15 mg cash-pay sits around $1,000 to $1,350 per month, dropping to roughly $25 to $200 with insurance coverage and a manufacturer savings card. LillyDirect Zepbound vials are about $349 to $549 per month and have largely closed the gap that previously made compounded microdosing the only affordable option.

Can I microdose compounded semaglutide?

It is still possible through some 503A compounding pharmacies operating on a patient-specific prescription, but the supply has tightened materially since the FDA removed semaglutide and tirzepatide from the drug-shortage list in 2024 and 2025. The legal basis that allowed routine 503B bulk compounding ended with that decision. Microdose-specific 503A compounding continues in some clinics, often at higher prices than during the shortage. The FDA has issued repeated cautions about non-503A-compliant compounded products — incorrect doses, salt-form confusion, and contamination among them.

Is microdosing legal in 2026?

Microdosing itself is not regulated by the FDA — physicians may prescribe FDA-approved GLP-1s off-label at any dose. What is regulated is the source. Splitting doses from a labeled Wegovy or Zepbound pen under your prescriber's direction is legal. A 503A compounding pharmacy can fill a patient-specific prescription for a sub-labeled dose where the prescriber has a documented clinical reason. What is not legal: routine 503B bulk compounding of semaglutide or tirzepatide outside the now-ended shortage exemption, and self-sourcing peptide vials from grey-market or research-chemical vendors.

Can I microdose after stopping a full GLP-1 dose for maintenance?

This is one of the most common reasons patients ask about microdosing, and it is the strongest off-label use case. The STEP-1 extension (Wilding 2022) showed roughly two-thirds regain within 12 months of a full stop, while STEP-4 and SURMOUNT-4 showed continued labeled-dose treatment held or extended the loss. A sub-labeled maintenance dose — semaglutide 0.25 to 0.5 mg weekly or tirzepatide 2.5 mg weekly — has biological plausibility for holding most of the loss with fewer side effects and lower cost. Trial evidence at maintenance microdoses does not yet exist; discuss it with your prescriber rather than self-tapering.

How do I split a Wegovy or Zepbound pen for microdosing?

Do not do this on your own. The Wegovy and Zepbound pens are calibrated for fixed weekly doses (0.25, 0.5, 1.0, 1.7, 2.4 mg for Wegovy; 2.5, 5, 7.5, 10, 12.5, 15 mg for Zepbound). They are not designed for fractional dosing, and the small volumes involved make accurate measurement difficult. Some clinicians work with compounding pharmacies to dispense vial-and-syringe formulations specifically for sub-labeled dosing under prescription. If cost is the only barrier, LillyDirect Zepbound vials at $349 to $549 per month or the Wegovy savings card are usually the safer route — see our [GLP-1 cost and insurance](/weight-loss/glp-1-cost-insurance/) guide for the full map.

GLP-1 Microdosing: What It Is, Who Does It, and What the Evidence Says

Quick answer

GLP-1 microdosing means taking a sub-therapeutic weekly dose of semaglutide or tirzepatide — typically one-quarter to one-eighth of the labeled chronic-weight-management dose. In practical numbers, that is 0.05 to 0.25 mg semaglutide per week or 0.5 to 2.5 mg tirzepatide per week, against labeled maintenance doses of 1.7 to 2.4 mg and 10 to 15 mg respectively. Patients pursue it for four honest reasons: cost (compounded sub-doses are materially cheaper than labeled retail), side-effect tolerance (many people cannot push past 1.0 mg semaglutide without intolerable nausea), recomposition without obesity-class BMI (adults with BMI 25–30 who do not qualify for labeled chronic weight management), and maintenance after a successful labeled-dose loss phase. The evidence base is uneven: no large randomized trial has tested microdose protocols, so all weight-loss efficacy data come from labeled-dose trials at 1.7 to 2.4 mg semaglutide or 10 to 15 mg tirzepatide. The honest verdict is that microdosing is a reasonable strategy for two of the four motivations (intolerance and supervised maintenance) and a weakly supported one for the other two (recomposition and “longevity”).

Who this is for / not for

Good fit if:

• You are considering microdosing — compounded or split-vial — to reduce cost or side effects of a labeled GLP-1.
• You finished a successful labeled-dose loss phase and are weighing a sub-labeled maintenance protocol instead of a full stop. See rebound weight gain after stopping GLP-1 for the broader maintenance map.
• You have a BMI between 25 and 30 with no labeled chronic-weight-management indication and want to think clearly about whether sub-dose appetite suppression is worth the trade-offs.
• You are a clinician, partner, or family member looking for a balanced summary of what is actually known.

Not a fit if:

• You have a personal or family history of medullary thyroid carcinoma, MEN2, prior pancreatitis without specialist clearance, or are pregnant, breastfeeding, or planning pregnancy in the near term. The class warnings still apply at any dose.
• You have type 2 diabetes and the GLP-1 is part of your glycemic regimen. Stopping or sub-dosing should be routed through your endocrinologist, not a microdosing protocol picked from this article.
• You are looking for STEP-1- or SURMOUNT-1-magnitude weight loss. Microdosing produces proportionally less.
• You are considering self-sourcing peptide vials from grey-market or research-chemical sellers. That is outside the scope of this article and is not safe.

What microdosing actually means (and what it does not)

The clearest way to draw the line is by weekly dose against where labeled trials measured efficacy.

Two things to keep clear. First, the FDA-approved chronic-weight-management indications for Wegovy and Zepbound use the therapeutic-dose row — every published efficacy number you have read about (the STEP and SURMOUNT averages) came from that range. Second, the labeled starter dose is itself a titration step, not a maintenance dose: efficacy at 0.25 mg semaglutide was never the design endpoint of any phase 3 weight-loss trial. Microdosing protocols repurpose dose levels that the trial program treated as transitional.

For background on the drug class, see the GLP-1 weight loss overview. For a brand-by-brand head-to-head, GLP-1 medications compared covers Ozempic, Wegovy, Mounjaro, and Zepbound.

Why people microdose — the 4 honest motivations

Cost

Compounded GLP-1 at sub-doses is materially cheaper than labeled retail — typically $99 to $200 per month for compounded semaglutide and $199 to $350 for compounded tirzepatide, against $1,000 to $1,350 cash for labeled Wegovy or Zepbound auto-injectors. For uninsured patients or those whose plans exclude weight-loss drugs, the cost differential has been the single largest driver of microdosing demand. The 2024 LillyDirect Zepbound vial program at $349 to $549 per month has narrowed that gap considerably; the full pricing map is in GLP-1 cost and insurance.

Side-effect tolerance

A meaningful minority of patients cannot tolerate the labeled escalation past 1.0 mg semaglutide or 7.5 mg tirzepatide. The choice for those patients is usually between staying at a sub-therapeutic dose indefinitely or stopping the medication altogether. A sustained sub-labeled dose with manageable side effects often produces better long-term outcomes than the labeled dose did during the brief attempt to reach it.

Recomposition without obesity-class BMI

Adults with BMI 25 to 30 do not qualify for the FDA-approved chronic-weight-management indications, but appetite suppression is still appealing — for body recomposition, athletic preparation, or perceived “metabolic optimization.” This is the motivation with the weakest evidence base and the largest gap between marketing claims and trial reality. It is also the motivation most associated with unintended overshoot and the visible facial-volume loss covered in Ozempic face and weight loss.

Maintenance after weight loss

The STEP-1 extension (Wilding 2022) showed roughly two-thirds regain within 12 months of a full stop. STEP-4 and SURMOUNT-4 showed that continued labeled-dose treatment holds the loss. Microdosing as maintenance is biologically plausible — keep some GLP-1 receptor occupancy without the full labeled dose’s cost or side effects — but has not been formally tested in long-term phase 3 trials.

What the evidence actually shows

There is no large randomized trial of microdose semaglutide or tirzepatide for weight loss. What does exist:

• Phase 1 and early dose-finding data. The dose-response work that informed the STEP and SURMOUNT designs (Davies 2017, Frias 2018, Frias 2019) shows that 0.25 mg semaglutide weekly produces approximately 1.5 to 3 percent weight loss at 12 weeks. Meaningful, but far below the roughly 15 percent at 68 weeks that the labeled 2.4 mg dose produced in STEP-1.
• Dose-response data for tirzepatide. SURMOUNT-1 (Jastreboff 2022) tested 5, 10, and 15 mg weekly. The 5 mg arm produced about 15 percent weight loss at 72 weeks, the 10 mg arm 19.5 percent, and the 15 mg arm 20.9 percent. The dose-response curve clearly flattens at higher doses; sub-therapeutic doses produce proportionally less loss with a steeper, not shallower, slope at the low end.
• Clinic-reported series. Compounding-pharmacy-linked clinics have reported case series suggesting 5 to 8 percent body-weight loss at 6 months on quarter-dose protocols, with markedly fewer side effects than labeled dosing. These are not blinded or controlled. Treat them as hypothesis-generating, not as evidence of equivalent efficacy.
• Maintenance evidence. STEP-4 (Rubino 2021) and SURMOUNT-4 (Aronne 2024) tested continuation of the loss-phase dose, not a reduced one. Whether a sub-labeled maintenance dose holds most of the loss is biologically plausible but unproven at the trial level.

The honest take: microdosing produces proportionally less weight loss than labeled doses. If you want the 15 to 22 percent loss seen in STEP-1 and SURMOUNT-1, you need the labeled dose. If you want 3 to 8 percent loss with substantially fewer side effects and lower cost, microdosing can deliver that — but be clear about which trade you are making.

The 3 common protocols (and the math)

Three named protocols capture most of what circulates in clinics.

The pulsed protocol deserves a footnote. Semaglutide’s half-life is roughly 1 week, so a 2-on/2-off schedule produces inconsistent blood levels and irregular appetite response. The biology favors continuous low-dose exposure over intermittent full-dose exposure. For the head-to-head between the underlying molecules and how dose ranges differ, semaglutide vs tirzepatide covers the comparison.

Cost: microdosing vs full dose vs compounded

Typical 2026-Q2 U.S. monthly cost estimates, cash-pay and insured.

A few things stand out. Cash-pay labeled cost is 5 to 10× the compounded microdose cost. Insured cost — when your plan covers the drug — is broadly comparable to or cheaper than compounded microdosing, which insurance does not reimburse. And LillyDirect Zepbound vials at $349 to $549 per month for the labeled dose have substantially closed the price gap that previously made compounded microdosing the only affordable cash-pay route. For 2026 brand pricing, savings programs, and a checklist for finding your real out-of-pocket figure, see GLP-1 cost and insurance.

Safety, side effects, and what we do not yet know

Same side-effect profile, lower frequency. The class side effects — nausea, constipation, reflux, gallbladder events, hypoglycemia in patients on insulin or sulfonylureas — appear proportional to dose. Patients at microdose levels report fewer and milder side effects in clinical practice, which is consistent with the dose-response data from the STEP and SURMOUNT programs. The slow-stomach symptoms that drive most early discontinuations are dose-related and reversible — see gastroparesis and weight loss for the Sodhi 2023 / Smith 2024 evidence on persistent vs transient delayed emptying.

The same warnings still apply. The boxed warning for medullary thyroid C-cell tumors, the pancreatitis caution, the contraindication in pregnancy and breastfeeding, and the careful coordination required for patients on insulin or sulfonylureas apply at any dose. Microdosing does not change the screening you should do before starting. See weight loss drug safety for the class-wide picture and pancreatitis and weight loss for the trial-data context behind the pancreatitis caution.

The unknowns. Long-term safety of indefinite sub-therapeutic GLP-1 dosing has not been studied at the trial level. Whether sub-labeled dosing over decades is safer than labeled dosing is unknown — the dose-response curve for adverse events at the very low end is not well characterized, especially for the rare events that matter most (pancreatitis, gallbladder disease, thyroid C-cell signals). SELECT (Lincoff 2023) and the ongoing cardiovascular outcome programs are reassuring at labeled doses; the equivalent data at microdoses does not exist.

Compounded supply risk. This is the practical safety issue for most patients. The FDA has issued repeated safety communications since 2023 about adverse events from non-503A-compliant compounded GLP-1 products — incorrect doses, contamination, salt-vs-free-base confusion, and product from non-licensed online sellers. Quality varies pharmacy to pharmacy. Use a U.S. state-licensed 503A pharmacy with a real prescription, or stick with labeled product.

Compounded GLP-1 microdosing — the legal and supply picture in 2026

The 2024 and 2025 FDA decisions removing semaglutide and tirzepatide from the drug-shortage list ended the legal basis for routine 503B bulk compounding of either molecule. Compounders were given a wind-down window through early 2025; routine bulk supply for the cash-pay market is no longer compliant.

Microdosing demand is still met by some 503A compounding pharmacies operating on a patient-specific-prescription basis. A 503A pharmacy may compound a sub-labeled dose where the prescriber has a documented clinical reason — most commonly intolerance of the labeled dose, or a sub-labeled maintenance protocol after a successful loss phase. Supply has tightened materially since 2024, and prices have risen. Many of the cash-pay telehealth programs that drove the 2022–2024 compounded-GLP-1 market have either narrowed product lines, raised prices, or shifted to labeled product through LillyDirect.

The 2024 launch of the LillyDirect Zepbound vial program — labeled-dose vials at $349 to $549 per month — has reshaped the economics. For a patient choosing between $200/month compounded microdose semaglutide and $349/month labeled Zepbound at the 2.5 mg starter dose, the labeled product is now the safer route at a comparable price. Novo Nordisk has at times offered a Wegovy cash-pay savings program with a comparable discount; verify current pricing on the manufacturer site.

Honest verdict — when microdosing is reasonable, when it is not

The case-by-case verdict, captured as a table.

Two notes. The “supervised maintenance” row is the only one where biology aligns with a real trial dataset — STEP-4 and SURMOUNT-4 both showed continued GLP-1 exposure holds the loss, even though neither trial tested sub-labeled maintenance specifically. Pair it with the lifestyle anchors covered in our rebound weight gain after stopping GLP-1 framework. The “intolerance” row is pragmatic rather than evidence-based — a sustained 0.5 mg semaglutide is better than a failed attempt at 2.4 mg, but the trial efficacy data for that dose pair simply does not exist.

If you are weighing how the comparison between molecules changes at sub-labeled doses, the dose-response curves favor tirzepatide at quarter-dose more strongly than they do at labeled dose — the SURMOUNT-1 5 mg arm landed near STEP-1’s 2.4 mg result. The trade-off discussion is in semaglutide vs tirzepatide, and the broader prescription landscape is in prescription weight loss medications and preserving muscle during weight loss for the resistance-training and protein anchors that protect lean mass on any GLP-1 dose.